Alcobra Ltd., of Tel Aviv, Israel, named David Baker, who is currently chief commercial officer, interim CEO, and appointed Yaron Daniely chairman of the board.
Altimmune Inc., of Gaithersburg, Md., named Sybil Tasker chief medical officer.
Amag Pharmaceuticals Inc., of Waltham, Mass., appointed Helen Milton vice president of regulatory affairs.
Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., of Tokyo, appointed Mark Schwitzenberg vice president, marketing, urology and hospital business unit, and Paul Kang executive director, marketing sciences.
Bellicum Pharmaceuticals Inc., of Houston, named Alan K. Smith executive vice president, technical operations.
Cerecor Inc., of Baltimore, added Steven Boyd and Peter Greenleaf to its board.
Cytomx Therapeutics Inc., of South San Francisco, appointed Debanjan Ray chief financial officer and head of corporate development.
Five Prime Therapeutics Inc., of South San Francisco, added Garry Nicholson to its board.
Forge Therapeutics Inc., of San Diego, appointed Brian T. Dorsey, Mario Polywka, John Schmid, and Steve Worland to its board.
Insmed Inc., of Bridgewater, N.J., named Paolo Tombesi chief financial officer, and Paul Streck chief medical officer. Additionally, the company appointed Eugene Sullivan chief product strategy officer.
Lysogene SA, of Neuilly-sur-Seine, France, named Philippe Mendels-Flandre chief operating officer.
Nicox SA, of Sophia Antipolis, France, added Lauren P. Silvernail to its board.
Oryzon Genomics SA, of Barcelona, Spain, appointed Roger Bullock chief medical officer.
Prothena Corp. plc, of Dublin, appointed Sarah Noonberg chief medical officer.